miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26064968
PubMed Central
PMC4433647
DOI
10.1155/2015/941980
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- indoly aplikace a dávkování MeSH
- Kaplanův-Meierův odhad MeSH
- karcinom z renálních buněk farmakoterapie genetika patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- mikro RNA biosyntéza genetika MeSH
- nádorové biomarkery biosyntéza genetika MeSH
- patologická angiogeneze farmakoterapie genetika patologie MeSH
- progrese nemoci MeSH
- pyrroly aplikace a dávkování MeSH
- regulace genové exprese u nádorů MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sunitinib MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- indoly MeSH
- mikro RNA MeSH
- MIRN155 microRNA, human MeSH Prohlížeč
- MIRN484 microRNA, human MeSH Prohlížeč
- nádorové biomarkery MeSH
- pyrroly MeSH
- sunitinib MeSH
Background. Sunitinib is a tyrosine kinase inhibitor used in the treatment of metastatic renal cell carcinoma. The main difficulty related to the treatment is the development of drug resistance followed by rapid progression of the disease. We analyzed tumor tissue of sunitinib treated patients in order to find miRNAs associated with therapeutic response. Methods. A total of 79 patients with metastatic renal cell carcinoma were included in our study. miRNA profiling in tumor tissue samples was performed by TaqMan Low Density Arrays and a group of selected miRNAs (miR-155, miR-374-5p, miR-324-3p, miR-484, miR-302c, and miR-888) was further validated by qRT-PCR. Normalized data were subjected to ROC and Kaplan-Meier analysis. Results. We reported decreased tissue levels of miR-155 and miR-484 as significantly associated with increased time to progression (miR-155: median TTP 5.8 versus 12.8 months, miR-484: median TTP 5.8 versus 8.9 months). Conclusion. miR-155 and miR-484 are potentially connected with sunitinib resistance and failure of the therapy. miR-155 is a known oncogene with direct influence on neovascularization. Biological role of miR-484 has to be clarified. Stratification of patients based on miRNA analysis would allow more personalized approach in therapy of metastatic renal cell carcinoma.
Central European Institute of Technology Masaryk University 625 00 Brno Czech Republic
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic
Department of Pharmacology Faculty of Medicine Masaryk University 625 00 Brno Czech Republic
Zobrazit více v PubMed
Rini B. I., Atkins M. B. Resistance to targeted therapy in renal-cell carcinoma. The Lancet Oncology. 2009;10(10):992–1000. doi: 10.1016/S1470-2045(09)70240-2. PubMed DOI
Bex A., Kroon B. K., de Bruijn R. Is there a role for neoadjuvant targeted therapy to downsize primary tumors for organ sparing strategies in renal cell carcinoma? International Journal of Surgical Oncology. 2012;2012:6. doi: 10.1155/2012/250479.250479 PubMed DOI PMC
Mlcochova H., Hezova R., Stanik M., Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urologic Oncology: Seminars and Original Investigations. 2014;32(1):41.e1–41.e9. doi: 10.1016/j.urolonc.2013.04.011. PubMed DOI
Wang C., Hu J., Lu M., et al. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Scientific Reports. 2015;5, article 7610 doi: 10.1038/srep07610. PubMed DOI PMC
Mishra P. J. MicroRNAs as promising biomarkers in cancer diagnostics. Biomarker Research. 2014;2(19) doi: 10.1186/2050-7771-2-19. PubMed DOI PMC
Hansen T. F., Carlsen A. L., Heegaard N. H., Sørensen F. B., Jakobsen A. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. British Journal of Cancer. 2015;112(4):624–629. doi: 10.1038/bjc.2014.652. PubMed DOI PMC
White N. M. A., Bao T. T., Grigull J., et al. MiRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. The Journal of Urology. 2011;186(3):1077–1083. doi: 10.1016/j.juro.2011.04.110. PubMed DOI
Li S., Chen T., Zhong Z., Wang Y., Li Y., Zhao X. MicroRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Molecular Medicine Reports. 2012;5(4):949–954. doi: 10.3892/mmr.2012.779. PubMed DOI PMC
Wojcicka A., Piekielko-Witkowska A., Kedzierska H., et al. Epigenetic regulation of thyroid hormone receptor beta in renal cancer. PLoS ONE. 2014;9(5) doi: 10.1371/journal.pone.0097624.e97624 PubMed DOI PMC
Biswas S., Troy H., Leek R., et al. Effects of HIF-1α and HIF2α on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. Journal of Oncology. 2010;2010:14. doi: 10.1155/2010/757908.757908 PubMed DOI PMC
Kong W., He L., Richards E. J., et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014;33(6):679–689. doi: 10.1038/onc.2012.636. PubMed DOI PMC
Prior C., Perez-Gracia J. L., Garcia-Donas J., et al. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS ONE. 2014;9(1) doi: 10.1371/journal.pone.0086263.e86263 PubMed DOI PMC
Vecchione A., Belletti B., Lovat F., et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(24):9845–9850. doi: 10.1073/pnas.1305472110. PubMed DOI PMC
Li A., Yu J., Kim H., et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clinical Cancer Research. 2013;19(13):3600–3610. doi: 10.1158/1078-0432.CCR-12-3092. PubMed DOI PMC
Zearo S., Kim E., Zhu Y., et al. MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. BMC Cancer. 2014;14(1, article 200) doi: 10.1186/1471-2407-14-200. PubMed DOI PMC
Kjersem J. B., Ikdahl T., Lingjaerde O. C., Guren T., Tveit K. M., Kure E. H. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Molecular Oncology. 2014;8(1):59–67. doi: 10.1016/j.molonc.2013.09.001. PubMed DOI PMC
Bimpaki E. I., Iliopoulos D., Moraitis A., Stratakis C. A. MicroRNA signature in massive macronodular adrenocortical disease and implications for adrenocortical tumourigenesis. Clinical Endocrinology. 2010;72(6):744–751. doi: 10.1111/j.1365-2265.2009.03725.x. PubMed DOI PMC
Wang K., Long B., Jiao J.-Q., et al. MiR-484 regulates mitochondrial network through targeting Fis1. Nature Communications. 2012;3, article 781 doi: 10.1038/ncomms1770. PubMed DOI
